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ORIGINAL ARTICLES 
Recommendations for Prevention of Hepatitis A Based on a 
Cost-Effectiveness Analysis 
Guy Tormans, Pierre Van Damme, and Eddy Van Doorslaer 
Background. Hepatitis A viral infection poses a substantial risk for travelers from low-endemic countries visiting high-endemic 
destinations. In this study, the general indications for the optimal prevention of hepatitis A are derived using a cost-effectiveness 
analysis based on the risk exposure determined by frequency and duration of travel as well as natural immunity. 
Methods. Three possible hepatitis A prevention strategies are compared to no prophylaxis: active immunization; an initial screening 
for HAV followed by active immunization of susceptible travelers; and passive immunization with immune globulins. Using a 
number of baseline assumptions, a scenario for travel from low- to high-endemic countries and an average travel duration and 
frequency rate, threshold values were obtained comparing active versus passive immunization. 
Results. The study shows that, for travelers not expected to journey more than twice in a 10-year period, passive immunization 
is the most cost-effective prophylaxis for travel from both very-low or low-to-high endemic areas. For more frequent travel, 
vaccination is more cost effective, as well as for journeys of 6-months' duration or longer. As well, pretravel screening before 
vaccination was shown to be worthwhile, except when the probability of natural immunity is low. 
Conclusions. As the results indicate, the cost effectiveness of a strategy is related to several considerations: the prices of vaccine 
and screening tests, travel destinations and endemic conditions, frequency and duration of travel, and natural immunity. A 
decision-tree-based simulation model is helpful in determining the strategy to employ. ( J  Travel Med 1:127-135, 1994) 
It is known that the risk of infection with the hepa- 
titis A virus (HAV) is substantial for travelers from 
low-endemic countries to high-endemic destinations.' 
Although the incidence of hepatitis A is quite high, 
the disease-related morbidity and case fatality rate is 
low when compared to hepatitis B. Possible preven- 
tive strategies, when considered alongside advice on 
hygiene and dietary precautions, include passive and 
active immunization. Prophylaxis with immune globu- 
lin provides relatively cheap, but short-term, protec- 
tion, whereas the recently developed active vaccine 
gives long-term protection, but at greater cost, since 
the full vaccination schedule requires three injections. 
However, it is possible to perform a screening test to 
assess the possibility of natural immunity. In its re- 
cently published protocol for vaccination requirements 
for hepatitis A the World Health Organization (WHO) 
recommends screening (before possible vaccination) 
of all people born and raised in developing countries 
and for people born before 1945 in industrialized coun- 
tries. This strategy prevents wasting of vaccines.2 
Correspondence to the editor published in other jour- 
n a l ~ ~ - ~  has revealed that individual practitioners in 
travel clinics have difficulty in making balanced deci- 
sions about vaccination protocols because of the com- 
plexities involved. Decisions are probably no less dif- 
ficult for the individual t ra~e ler .~  Clearly, a rational 
prevention policy requires consideration of the rela- 
tive costs and benefits of the various possible strategies. 
The present authors have developed a decision 
tree-based model to calculate the cost effectiveness 
(CE) of the various alternative strategies for HAV pre- 
vention in Belgian travelers to high-endemicity areas." 
It was shown that the most cost-effective choice de- 
pends on a large number of epidemiologic, behav- 
ioural, and economic parameters. Since, in general, it 
was found that prevention was not cost saving, two 
conclusions were formulated in advance: 
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1. If the objective is cost minimization, no hepatitis 
A prevention should be undertaken because in- 
fections can only be prevented with additional 
If there is no budgetary restriction, the optimal 
strategy is clearly the most effective, i.e., vaccina- 
tion. 
cost. 
2. 
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Using this decision tree-based model, the authors 
tried to answer the more difficult question of which 
strategy was the most cost effective when a limited 
budget for hepatitis A prevention is a given. In this 
article, some general indications for the optimal allo- 
cation of any given hepatitis A budget are derived 
based on two main factors: the risk exposure as deter- 
mined by frequency of travel and duration of stay; 
and the natural immunity. The latter is determined by 
endemicity in the country of origin and age-specific 
prevalence in the population. 
Methods 
Three possible strategies for prevention of HAV 
infection in travelers will be compared to doing noth- 
ing: active immunization with an inactivated hepati- 
tis A vaccine (SrnithKline Beecham Biologicals, 
Rixensart, Belgium),"J' first screening for the pres- 
ence of HAV antibodies in the blood and then vacci- 
nating only susceptible travelers; and passive immu- 
nization with immune g10bulin.l~ The costs and ef- 
fects associated with each of these three alternatives 
will be calculated for three levels of endemicity in the 
country of origin (moderate, low, and very low), for 
short and long durations of stay and for high and low 
travel frequency. The basic decision tree for the simu- 
lation model is represented in Figure 1. 
The model is used to calculate the expected in- 
cremental net medical care costs per infection pre- 
vented (i.e., additional costs of prevention minus cost 
savings). Obviously the results are highly dependent 
on the estimates of the various probabilities of immu- 
nity and infection. These estimates are based on the 
best evidence available in the literature. The Belgian 
data,1°J4JS which were collected based on travel 
behavior and costs, were assumed to be valid for the 
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Figure 1 Basic decision tree 
calculation based on other Western European coun- 
tries and the United States. Sensitivity analysis was 
used extensively to assess the sensitivity of results to 
assumptions made about key model parameters. 
Threshold analysis was performed to provide an indi- 
cation of which strategy is optimal over which range 
of a certain parameter (e.g., the higher the prevalence 
of immunity, the more likely screening will be cost- 
effective. 
Because in the baseline analysis, only direct medi- 
cal care costs are considered, the implicit (narrow) 
viewpoint taken for analysis is that of the payer for 
medical care, which may be the patient or some pub- 
lic or private insurer. In the sensitivity analysis, this 
viewpoint will be somewhat broadened to a more 
societal perspective when indirect costs attributable 
to (for example) productivity or work losses are in- 
cluded. 
Disease and Epidemiology 
Hepatitis A is an acute inflammatory disease of 
the liver caused by HAV. The HAV virus is spread by 
the feco-oral route, usually by person-to-person con- 
This means that transmission is facilitated by 
poor hygiene and sanitation. HAV has a worldwide 
distribution closely related to levels of economic de- 
velopment. Transmission often occurs in epidemic clus- 
ters.I8 The continuous decline in incidence of HAV in 
many developed and developing countries can be at- 
tributed to better conditions of sanitation and improve- 
ment in standards of living. As the endemicity of HAV 
decreases, the average age of exposure and subsequent 
infection has shifted to an older age group wherein 
clinical illness is more frequent. 
HAV disease is usually self-limiting, and it shows 
a variety of clinical features.19 The severity of illness is 
age dependent. Among children and newborns, HAV 
infection is usually asymptomatic and mostly anicteric. 
Among adults, symptomatic infection occurs in 80 to 
HAV infection only rarely has a fulminant evolu- 
tion. The case-fatality rate is low. It ranges from .02% 
to 1.5%,22 depending on the age of onset of hepatitis 
A infection. Chronic disease has not been documented, 
but in 6 to 10% of clinical cases, a relapse in liver 
inflammation may O C C U ~ . ~ ~ J ~  
Baseline Estimates 
Infection Patterns: Because the benefits of HAV 
prevention in travelers originating from high-endemic 
countries are negligible, only populations from lower- 
endemic countries will be considered. With reference 
to data from the Centers for Disease the 
following three regions with typical HAV infection pat- 
terns can be defined: 
90%.20921 
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1. Very-low-endemic regions are characterized by an 
average annual HAV attack rate of .003% (3/ 
100,000) and an average prevalence of HAV an- 
tibodies of 20%. This pattern is seen in the 
Scandinavian countries. 
The annual attack rate for hepatitis A infection 
in low-endemic regions is estimated at an aver- 
age of .01%, and the prevalence of HAV immu- 
nity is 25%. Examples include North America, 
Switzerland, and Germany. 
The average annaul attack rate for hepatitis A in- 
fection in moderately-endemic regions is .05’%0, 
with an average HAV immunity prevalence of 
45%. Southern, Central, and Eastern European 
countries represent this third pattern. 
2. 
3. 
The distinction between various regions of origin 
is important for two reasons. Firstly, the potential 
benefits of HAV screening increase with a rising preva- 
lence of immunity in the screened population. Sec- 
ondly, the higher the risk (i.e., the endemicity of HAV) 
in the home country, the greater the benefits are for 
protection against HAV infection. This is obviously 
an advantage of vaccination, which provides long-term 
protection (i.e., travelers remain protected after their 
return) as against the immune globulin, which can only 
offer short-term protection. The HAV prevalences 
given here are average data. Since the prevalence of 
HAV immunity rises with the age of the population in 
each of these three regions, the recommendations made 
for each region are dependent on the age of the target 
group. For the baseline calculations an average age of 
35 years has been assumed. 
Travel Characteristics: Belgian data indicate 
that the average duration of travel to high endemic 
countries is 25 days.Is Additionally, since the expected 
frequency of travel is so crucial to the economic re- 
sults, the frequency of travel in the first scenario cal- 
culations has already been varied. Frequency ranged 
from one 25-day period in the first year of a 10-year 
period to one 25-day visit per year every year over 10 
years. In order to illustrate the importance of ranging 
this frequency, recent travel behavior dataIs is referred 
to, and this shows that 65% of the traveler popula- 
tion studied (n = 1423) intended to repeat a journey 
in the future: 39% of this number intended to repeat 
their journey once every year; 47% once every 2 or 3 
years; and 14% every 5 years. 
As a baseline assumption for the annual attack 
rate of HAV in susceptible travelers to endemic coun- 
tries a figure of 3.6% is used as reported by Steffen.’ 
This figure is adapted to the duration of a traveler’s 
stay abroad. This attack rate varies in the sensitivity 
analysis according to the travel destination and con- 
ditions. 
Clinical Course ofHAVInfection: It is assumed 
that 10% of all HAV infections among travelers are 
asympt~rnatic.”~~ This assumption was based on sur- 
veys. These surveys indicate that about 50% of symp- 
tomatic infections will be mild and treatable by a gen- 
eral practitioner. About 30% will develop a moderate 
HAV infection, which will require specialist treatment. 
The percentages of severe (i.e., the % requiring hospi- 
talization) and fulminant cases are estimated at 19.9% 
and 0.1 %, respectively. As has been suggested, relapse 
rates vary inversely with the severity of the clinical 
i n f e c t i ~ n . ~ ~ , ~ ~  Relapse rates are estimated at 9, 7, and 
2% after mild, moderate, and severe hepatitis A, re- 
spectively. The average costs of treating mild, moder- 
ate, severe, fulminant, and relapsing hepatitis were 
estimated at $342, $434, $2216, $22,152, $434 (U.S.) 
respectively (this estimation is based on the 1991 cost 
of Belgian health care).I4 In the baseline scenario, no 
indirect costs of HAV infections attributable to pro- 
ductivity losses were included. All costs in later years 
were discounted at a rate of 5%. 
HAV Prevention Strategies: The vaccination 
strategy is aimed at the active immunization of the 
entire target group with the HAV vaccine. However, 
because the vaccine is administered in two doses plus 
a booster (at 0,1, and 12 months), compliance-and 
therefore protection-is assumed to be less than com- 
plete. The authors’ assumption is that 100% will re- 
ceive the first dose, 60% will receive the second dose, 
and only 50% will receive the booster after 1 year 
(Table 1). The rate and duration of protection with 
only one dose, with two doses, and with the full sched- 
ule are estimated based on the currently available evi- 
dence on seroconversion The costs of vac- 
cination are assumed to be $30 for one dose plus $10 
for the costs of administering the vaccine. 
To avoid the waste of expensive vaccine on irn- 
munizing the already immune, initial screening for 
HAV antibodies should be considered. The HAV anti- 
body screening test has a high sensitivity (99’%0) and 
specificity (99’X0).~’ The total cost of screening one 
traveler is estimated at $30. Compliance with the vac- 
cination schedule of those found to be susceptible af- 
ter screening is assumed to be identical to the compli- 
ance of those vaccinated without prior screening. 
Until recently, the recommended prevention strat- 
egy for travelers to high-endemic regions was passive 
immunization with the administration of immune 
globulins. The protection rate is estimated a t  85%, 
and protection at the recommended dose of 0.02 ml 
per kg lasts for 3 m ~ n t h s . ~ ~ J ~  Compliance may also be 
incomplete for passive immunization in the sense that 
individuals may not always be willing or  able to re- 
ceive immune globulins before each trip. Estimated 
compliance is at 100% for the first trip and at 50% 
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for subsequent trips. Unit costs of passive immuniza- 
tion, i.e., the purchase and administration of one dose, 
are estimated at $24 (U.S.), which is a weighted aver- 
age of the cost of cheap (aspecific) and more expen- 
sive (specific) immune globulins, according to the rela- 
tive proportion of each used in different Belgian travel 
clinics . 
For a summary table of all baseline assumptions 
of the model see Table 1. 
Results and Discussion 
For each of the three preventive strategies and 
for each type of region of origin, the expected number 
of infections and the expected direct medical costs in- 
curred were calculated using the baseline assumptions. 
Comparison to the doing nothing strategy-which 
proves for all scenarios to be the cheapest, but the 
least effective-allows the computation of each strat- 
egy's cost effectiveness, i.e., the net medical cost per 
HAV infection prevented. 
Baseline Cost-Effectiveness 
In Figure 2, the cost effectiveness (CE) ratios for 
the three intervention strategies compared to doing 
nothing are presented for travelers from a low-endemic 
country (e.g., North America, Switzerland, or Ger- 
many)'* to high-endemic regions (e.g., developing 
countries). On the horizontal axis, the expected travel 
frequency in the subsequent 10 years is varied from 
once times 25 days to 10 times 25 days. For those not 
expected to undertake such a journey more often than 
once or twice, passive immunization with immune 
globulin is the most cost-effective preventive action, 
For a traveler traveling once in a 10-year period, the 
expected net medical cost under a passive immuniza- 
tion strategy amounts to $22.8 (U.S.), whereas the 
probability of an infection in the next 10 years is re- 
duced from 0.25% (i.e., the weighted average of the 
incidence at home and abroad) to 0.087%. Combin- 
ing these two in a cost-effectiveness ratio results in an 
expected cost of $14,454 (U.S.) per HAV infection pre- 
vented. Although vaccinating this traveler would fur- 
ther reduce the probability of infection to 0.035%, 
the investment needed to obtain this reduction 
amounts to $82.5 (U.S.), which results in a net medi- 
cal cost per infection prevented of $39,316 (U.S.). As 
soon as the same traveler is expected to travel three or 
more times in 10 years, it becomes more cost effective 
to vaccinate before the first trip. The subsequent in- 
creased risk of HAV infection would require repeated 
passive immunization. This practice would consider- 
ably increase the cost per infection prevented. 
It can be shown that the same conclusions hold 
for travelers leaving from very-low-endemic regions 
(e.g., Sweden), that is to say as soon as travelers are 
expected to go to high-endemic regions for 25 days 
more than twice in a 10-year period, vaccination be- 
comes the most cost-effective alternative. Because 
travelers leaving from moderately-endemic regions 
(e.g., Greece) also remain protected in their living en- 
vironment after their return, active immunization is 
more cost effective than immune globulin if these 
travelers are expected to go abroad more than once in 
a 10-year period. 
The first step is to decide between vaccination or 
administration of immune globulins. The decision 
about whether to screen or not to screen before vacci- 
nation will be dealt with later. The effect of the age of 
the traveler on the model and the contribution of 
screening will also be discussed below. 
Costs per HAV infection prevented 
4 Active Immunization 
-8- Screening & Active Immunization 
4 Passive Immunization 
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Figure 2 Costs per infection prevented 
in U.S. dollars. (On the vertical axis the 
costs per infection prevented are dis- 
played for the three prevention strategies 
compared to doing nothing for travelers 
leaving from low-endemic regions. The 
horizontal axis reflects the travel behavior, 
which varies from once in a 10-year pe- 
riod to 10 times in a 10-year period). 
1 2 3 4 5 6 7 8 9 10 
Frequency of travel in a 10-year period 
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Table 1 Overview of Baseline Assumptions 
Epidemiologic Data Very-Low-Endemic Region Low-Endemic Region Moderate-Endemic Region 
Country of Origin 
(“h) (%) (%) 
HAV-Prevalence 20 25 45 
HAV-Annual incidence 0.003 0.01 0.05 
Developing countries 
HAV-Annual incidence 3.6 
Clinical Data: HAV % 
~ ~ 
Clinical Manifestation 
Symptomatic hepatitis 
Mild hepatitis 
Moderate hepatitis 
Severe hepatitis 
Fulminant hepatitis 
90 
50 
30 
19.9 
0.1 
Relapse after mild hepatitis 9 
Relapse after moderate hepatitis 7 
Relapse after severe hepatitis 2 
Vaccine Data: HAV Dose 1 Dose 2 Dose 3 
Compliance 
Duration of protection 
Protection rate 
100% 
1 year 
90% 
60 % 50% 
2 years 10 years 
98% 99% 
Screening Data (YO) 
Parameters 
Sensitivity of the screening test 
Specificity of the screening test 
9 9  
9 9  
Passive Immunization Data 
Protection rate 85% 
Duration of protection of 1 dose 
Compliance: first dose 100% 
Compliance: second dose 50% 
90 days 
Economic Data $ (US.) 
Unit cost for treating: 
Mild hepatitis 342 
Severe hepatitis 2,216 
Moderate hepatitis 434 
Fulminant hepatitis 22,152 
Relapsing hepatitis 434 
Unit cost for: 
Vaccination 40 
Screening 30 
Passive immunization 24 
Discount rate 5 %  
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Table 2 Optimal Strategy by Region of Origin, Travet Frequency, and Duration of Stay 
Expected Travel Frequency in 10 Years 
Region of Origin Once Twice Three Times 
or More 
Very-low-endemic or Ig’s: less than 180 days Ig’s: less than 90 days Vaccination 
Low-endemic region Vaccination: more than 180 days Vaccination: more than 90 days 
Moderate-endemic region Ig’s: less than 180 days Vaccination 
Vaccination: more than 180 days 
Vaccination 
Active or Passive Immunization? 
In Table 2 some general guidelines for the choice 
between the vaccine and immune globulin in HAV 
prevention are formulated based on the economic 
analysis. These recommendations are valid under the 
baseline assumptions listed in Table 1. 
In general, for the three considered regions of 
endemicity, it can be stated that for an expected travel 
frequency to a high-endemic region of three times or 
more in the next 10 years, vaccination is more cost 
effective, whereas passive immunization is more cost 
effective for travel frequencies of once in 10 years. 
The duration of travel can also be varied whereas the 
frequency is kept constant. Passive immunization 
remains the most cost-effective strategy for a single 
journey provided that the duration is less than the 
threshold value of 180 days. For journeys longer than 
6 months, vaccination becomes more cost effective, 
even for a single journey. 
For people with an expected travel frequency of 
twice in a period of 10 years, recommendations are 
dependent on the region of origin. Passive immuniza- 
tion is never the most cost effective alternative for 
travelers from a moderately endemic region, and for 
travelers from a low- or a very-low-endemic region, it 
is only so if the duration of the stay abroad is less 
than 90 days. In all other cases, active immunization 
is the preferred strategy from a cost-effectiveness point 
of view. 
Vaccination or Screening and Vaccination? 
Once the choice has been made for longer term 
protection, the next step is to consider whether or not 
to screen for hepatitis A antibodies. 
The availability of a sensitive and specific screen- 
ing test offers the opportunity of screening travelers 
first for the presence of HAV antibodies (IgG anti- 
bodies) and then vaccinating only susceptible persons. 
The objective is to avoid wasting vaccine on individu- 
als with already acquired natural immunity. 
Four parameters may affect the screening deci- 
sion as follows: (1) the expected prevalence of natural 
immunity in the target group (which is mostly depend- 
ent on age and degree of endemicity); (2) the cost of 
the vaccine; (3) the cost of the test; and (4) the sensi- 
tivity and specificity of the test. Although other means 
of testing for HAV antibodies, such as questionnaires 
and saliva tests, have been reported to be useful in 
that these avoid the need for a needle p~ncture,2~ blood 
tests are preferred because of their superior accuracy. 
Since the sensitivity and specificity of blood tests are 
close to loo%, this parameter can be kept constant in 
the decision making process. 
Figure 3 shows the results of varying the three 
other key parameters simultaneously. The cost of the 
test and the prevalence of HAV immunity are varied 
on the horizontal and the vertical axis respectively, 
For the baseline ($40 U.S.) and two other costs of the 
vaccine, the prevalence of HAV antibodies at which 
the costs per infection prevented under vaccination 
and those under screening and vaccination are equal 
has been calculated. By connecting these break-even 
points we obtained three lines for respective vaccine 
costs, which each divide the diagram into two areas: 
for all combinations below each line, vaccination is 
the most cost-effective strategy; above each line prior 
screening is optimal. 
An example follows to clarify the usefulness of 
the data presented in Figure 3. For German travelers30 
the following HAV-prevalence rates by age group have 
been reported: c20 years: 5%; 21-30 years: 5%; 31- 
40 years: 13%; 41-50 years: 28%; 51-60 years: 50%. 
It can be verified from Figure 3 that at a cost of the 
screening, $30 (U.S.), and for a vaccination cost of 
$40 (US.), immediate vaccination is the most cost- 
effective option for HAV-prevalence rates below 35%. 
This means that the threshold level for cost-effective 
screening for German travelers lies between the ages 
of 40 and 60 years. Therefore, above 50 years of age, 
screening before vaccination could be systematically 
proposed. The optimal choice will obviously vary with 
the endemicity of the region of origin and the age of 
the individual. 
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costs, the dotted threshold lines show the 
total of all combinations of the cost of the 
'' screening test and the prevalence rates 
of HAV-immunity atwhich both strategies 
are equally cost effective. For combina- 
tions above the lines screening plus vac- 
cination is more cost effective than imme- 
diate vaccination and vice versa. 
Price of the screening test 
Sensitivity Analysis 
When travel destination and circumstances are 
considered, to test the sensitivity of the results to 
changes in various key parameters, extensive sensitiv- 
ity analysis was performed. It is clear that destination 
and the circumstances of a proposed journey have a 
major impact on the risk of exposure to an HAV in- 
fection. The results of varying travel destinations and 
circumstances, and their associated estimated attack 
rates, are presented in Figure 4. The situation consid- 
ered in Figure 4 is one of travelers from low-endemic 
countries (e.g., North America) who expect to travel 
to Mediterranean countries compared to traveling to 
developing countries for 25 days, three times, in 10 
years. It can be seen that, in each case, the most cost- 
effective prevention strategy is vaccination. However, 
although the expected net medical costs for prevent- 
ing one HAV infection are estimated at no less than 
$239,000 (U.S.)-$180,606 (U.S.) for a traveler leav- 
ing for a Mediterranean area (annual attack rates 
0.018-0.13%0),' this decreases to $20,528 (U.S.) per 
250,000 
200,000 
150,Ooo 
100,000 
50,000 
0 
Costs per infection prevented ($) 
infection prevented for travelers to developing coun- 
tries. For hikers, the annual attack rate has been re- 
ported to be 20% during their stay abroad.' So if hy- 
giene conditions during the journey are expected to 
be quite low (e.g., hikers in developing countries), di- 
rect medical costs per infection prevented are calcu- 
lated at  $2,000-$3,000 (U.S.). 
In order to identify the most sensitive key param- 
eters, all parameters were increased by 10%. Figure 5 
shows the changes in the cost-effectiveness ratio ex- 
pressed as the percentage change from the baseline 
results. It can be seen that the cost-effectiveness (CE) 
ratios of some strategies are somewhat sensitive to 
assumptions regarding the attack rate abroad, i.e., the 
cost of the vaccine, the cost of the immune globulin, 
and to a lesser extent, to the traveler's compliance with 
the vaccination schedule. A 10% increase in the at- 
tack rate abroad causes an almost 8% decrease in the 
CE ratio. On the other hand, the results turn out to be 
somewhat insensitive to the costs of treating the HAV 
infections and the discount rate used. 
EBActive Immunization 
[IIDScreening & Active Immunization 
Figure4 Effect oftravel destination and 
circumstance. 
Mediterranean Developing Countries : Developing Countries : 
Usual Travel Trampers 
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Parameters : 10 % increase 
Attack rate at home 
Attack rate abroad 
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Figure 5 Sensitivity analysis: key param- 
eters. (Percentage changes in costs per 
infection prevented as a result of a 10 % 
increase in seven key parameters). 
Up to this point, the analysis has only included 
direct medical costs. Obviously the inactivity of HAV 
infected individuals also entails indirect costs of pro- 
ductivity losses. To the extent that HAV prevention 
results in reduced infection rates, it also serves to re- 
duce these indirect costs. The monetary valuation of 
these indirect costs may vary by country, but the CE 
ratios are linearly related to the estimated cost per 
day of inactivity due to an HAV infection. The aver- 
age number (weighted) of inactivity days due to any 
HAV infection (mild, moderate, severe, or fulminant) 
is estimated at 28.5 days. Consequently the net total 
costs (direct plus indirect) per infection prevented need 
to be adjusted for the number of infections prevented 
by 28.5 times the cost per day. Assuming the cost per 
day of inactivity to be $150 (U.S.), the baseline CE 
results of HAV prevention in travelers from low- to 
high-endemic countries for 25 days, three times in 10 
years, then becomes $16,252 (U.S.) for active immu- 
nization, $18,664 (US) for screening prior to active 
immunization and $17,565 (U.S.) for passive immu- 
nization. It is clear that the CE ratios are more fa- 
vourable the higher the estimated cost per day lost 
due to HAV. 
sive and active immunization. It was shown that pas- 
sive immunization remains the most cost-effective 
strategy for those expected to travel to high-endemic 
areas no more than twice over the next 10 years. For 
all other scenarios, it is worth considering a screening 
test before vaccination unless the probability of natu- 
ral immunity is low. 
What is shown is that cost-effectiveness results 
are very sensitive to some parameters (e.g., price of 
vaccine and screening test, travel destinations, and 
conditions), but not to others (cost of treatment of an 
HAV infection). Generally, inclusion of indirect costs 
attributable to HAV-related inactivity improves the cost 
effectiveness of HAV prevention. 
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